Economy/Home · Economy

[Breaking] Antrogen Applies for MFDS Approval of Phase 2 Trial Change for Knee Osteoarthritis Drug ANT-301... 63 Patients

Antrogen announced in a regulatory filing on the 26th that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of changes to the domestic Phase 2 clinical trial plan for ANT-301, a treatment for knee osteoarthritis. The clinical trial is a multicenter, randomized, double-blin

Oseong Kwon
Staff Reporter
4 min read
[Breaking] Antrogen Applies for MFDS Approval of Phase 2 Trial Change for Knee Osteoarthritis Drug ANT-301... 63 Patients
CBC News

Antrogen announced in a regulatory filing on the 26th that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of changes to the domestic Phase 2 clinical trial plan for ANT-301, a treatment for knee osteoarthritis.

The clinical trial is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the efficacy and safety of ANT-301 in patients with Kellgren-Lawrence (K&L) grade 3 knee osteoarthritis. It is scheduled to be conducted at approximately five clinical institutions in South Korea, with a target of 63 subjects (up to 66). The trial period is approximately 48 months from the date of Institutional Review Board approval.

The purpose of the trial is to evaluate the efficacy of the investigational drug in improving pain and function in the target knee, and to confirm its effects on pain, function, and structural improvement, as well as its safety. The trial consists of two stages: after safety is confirmed in a 'Safety run-in cohort' that assesses safety following repeated dosing, the 'Main cohort' will proceed. In the Main cohort, eligible subjects who meet the inclusion and exclusion criteria will be randomly assigned 1:1 to the placebo and investigational drug groups. Thereafter, efficacy will be evaluated according to the planned schedule in terms of pain, function, and structural improvement, while safety will be assessed through laboratory tests, vital sign monitoring, and the collection of adverse events.

Antrogen stated that whether the change is approved and the approval timeline will be determined by the MFDS's review outcome, and that the clinical trial schedule may change accordingly. It also explained that the probability of a clinical trial drug ultimately receiving final approval as a pharmaceutical product is statistically known to be around 10%, and that if results fall short of expectations during the clinical trial or product approval process, the company may change or abandon its commercialization plan.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.